Evidence map›Paper›PMID 37368094›Full record

ArticleClinical and experimental nephrology2023

Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease.

Hiroshi Kataoka, Yosuke Shimada, Tomonori Kimura, Saori Nishio, Shinya Nakatani, Toshio Mochizuki, Ken Tsuchiya, Junichi Hoshino, Fumihiko Hattanda, Haruna Kawano and 28 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 1 country.

Hiroshi KataokaDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Yosuke ShimadaIntelligent Systems Laboratory, SECOM CO., LTD. Mitaka, Tokyo, Japan.
Tomonori KimuraReverse Translational Research Project, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan.
Saori NishioDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Shinya NakataniDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine Osaka, Osaka, Japan.
Toshio MochizukiDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Ken TsuchiyaDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Junichi HoshinoDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Fumihiko HattandaDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Haruna KawanoDepartment of Urology, Department of Advanced Informatics for Genetic Disease, Juntendo University, Tokyo, Japan.
Kazushige HanaokaDepartment of General Internal Medicine, The Jikei University, Tokyo, Japan.
Sumi HidakaKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kanagawa, Japan.
Daisuke IchikawaDepartment of Nephrology and Hypertension, St Marianna University School of Medicine, Kanagawa, Japan.
Eiji IshikawaDepartment of Internal Medicine, Saiseikai Matsusaka General Hospital, Mie, Japan.
Kiyotaka UchiyamaDivision of Endocrinology, Metabolism and Nephrology Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Hiroki HayashiDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Shiho MakabeDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Shun ManabeDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Michihiro MitobeDepartment of Nephrology, Takeda General Hospital, Fukushima, Japan.
Akinari SekineDepartment of Nephrology, Toranomon Hospital, Tokyo, Japan.
Tatsuya SuwabeDepartment of Nephrology, Toranomon Hospital, Tokyo, Japan.
Hirayasu KaiPathophysiology of Renal Diseases, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Mahiro KurashigeNephrology and Hypertension, Department of Internal Medicine, The Jikei University, Tokyo, Japan.
Koichi SetaDepartment of Nephrology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Keiji ShimazuDepartment of Nephrology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Tomofumi MoriyamaDivision of Nephrology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Mai SatoDivision of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Tadashi OtsukaDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Kan KatayamaDepartment of Cardiology and Nephrology, Mie University Graduate School of Medicine, Mie, Japan.
Wataru ShimabukuroDepartment of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Takuya FujimaruDepartment of Nephrology, St. Luke's International Hospital, 9-1 Akashi-Cho, Chuo-Ku, Tokyo, Japan.
Kenichiro MiuraDepartment of Pediatric Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Koichi NakanishiDepartment of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Shigeo HorieDepartment of Urology, Department of Advanced Informatics for Genetic Disease, Juntendo University, Tokyo, Japan.
Kengo FuruichiDepartment of Nephrology, Kanazawa Medical University, Ishikawa, Japan.
Hirokazu OkadaDepartment of Nephrology, Saitama Medical University, Saitama, Japan.
Ichiei NaritaDivision of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan.
Satoru MutoDepartment of Urology, Juntendo University Nerima Hospital, Tokyo, Japan. s-muto@juntendo.ac.jp.ORCID http://orcid.org/0000-0002-5400-5195
Tokyo Women's Medical University · JPJuntendo University · JPHokkaido University · JPJikei University School of Medicine · JPNiigata University · JPToranomon Hospital · JPUniversity of the Ryukyus · JPFujita Health University · JPIjinkai Takeda General Hospital · JPJuntendo University Hospital · JPKanazawa Medical University · JPKeio University · JPKurume University · JPKyoto Medical Center · JPMie University · JPNational Center For Child Health and Development · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPOsaka City University · JPSaiseikai Nakatsu Hospital · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical practice guidelines recommend antihypertensive and tolvaptan therapies for patients with autosomal dominant polycystic kidney disease (ADPKD) in Japan. However, tolvaptan therapy may pose an economic burden. The Japanese Ministry of Health, Labour and Welfare supports patients with intractable diseases. This study aimed to confirm the impact of the intractable disease system in Japan on the clinical treatment of ADPKD.

methodsWe analyzed the data of 3768 patients with ADPKD having a medical subsidy certificate from the Japanese Ministry of Health, Labour and Welfare in 2015-2016. The following quality indicators were use: the adherence rate to the 2014 clinical practice guideline for polycystic kidney disease (prescription rates of antihypertensive agents and tolvaptan in this cohort) and the number of Japanese patients with ADPKD nationwide started on renal replacement therapy in 2014 and 2020.

resultsCompared with new applications from 2015 to 2016, the prescription rates of antihypertensives and tolvaptan for the indicated patients at the 2017 renewal application increased by 2.0% (odds ratio = 1.41, p = 0.008) and 47.4% (odds ratio = 10.1, p > 0.001), respectively. These quality indicators improved with antihypertensive treatment, especially in patients with chronic kidney disease stages 1-2 (odds ratio = 1.79, p = 0.013) and in those aged < 50 years (odds ratio = 1.70, p = 0.003). The number of patients with ADPKD who were started on renal replacement therapy in Japan decreased from 999 in 2014 to 884 in 2020 in the nationwide database (odds ratio = 0.83, p < 0.001).

conclusionsThe Japanese public intractable disease support system contributes to improvement of ADPKD treatment.

Indexed as

Polycystic Kidney, Autosomal DominantAntidiuretic Hormone Receptor AntagonistsAntihypertensive AgentsHumansJapanRegistriesTolvaptanAntidiuretic Hormone Receptor AntagonistsAntihypertensive AgentsTolvaptanAntihypertensiveAutosomal dominant polycystic kidney diseaseClinical indicatorIntractable diseaseQuality indicatorTolvaptan

Identifiers

PMID37368094
OpenAlexW4382181719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.